Donepezil CAS 120014-06-4 API Active Pharmaceutical Ingredient

Product Description:

Product Name: donepezil CAS NO: 120014-06-4

Synonyms:

2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimetho-xy-2,3-dihydroinden-1-one;

2,3-dihydro-5,6-dimetho-xy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-1h-inde;n-1-one;

N-Benzyl-4-[(5,6-dimetho-xy-1-indanon-2-yl)methyl] piperidi-ne;

Chemical & Physical Properties:

Appearance: White or almost white crystal powder

Assay :≥98%

Density: 1.141g/cm3

Boiling Point: 527.9℃at 760mmHg

Melting Point: 207℃

Flash Point: 273.1℃

Refractive Index: 1.578

Vapor Pressure: 3.11E-11mmHg at 25℃

Water Solubility: 2.931 mg/L

Storage: Store at -20℃

Safety Information:

RIDADR: UN 2811

Risk Statements: R36/37/38

Hazard Code: Xi

Safety Statements: S26; S36

Hazard Statements: H302+H312+H315+H319+H332+H335

Precautionary Statements:

P260+P262+P270+P280+P302+P352+P304+P340+P305+P351+P338+P402+P404+P411

Donepezil, marketed under the trade name Aricept, is a medication used in the palliative treatment of Alzheimer's disease. Donepezil is used to improve cognition and behavior of people with Alzheimer's, but does not slow the progression of or cure the disease.

Common side effects include loss of appetite, gastrointestinal upset, diarrhea, difficulty sleeping, vomiting, or muscle cramping.

It was developed by Eisai and Pfizer and is sold as a generic by multiple suppliers. Donepezil acts as a centrally acting reversible acetylcholinesterase inhibitor.Donepezil is another “nonclassic,” centrally acting, reversible, noncompetitive AChEI that was approved in 1997 for treatment of mild-to-moderate AD and dementia. Its selectivity for AChE is 570- to 1,250-fold that for butyrylcholinesterase, and it also exhibits greater affinity for brain AChE than for AChE in the periphery.

Acetylcholine is a neurotransmitter involved in neural signaling throughout the body. Donepezil is a reversible acetylcholinesterase inhibitor that readily crosses the blood-brain barrier to reduce the breakdown of acetylcholine. It has a half-life in circulation of about 70 hours. As acetylcholine modulates plasticity, excitability, and arousal in the central nervous system, donepezil is commonly used in the treatment of Alzheimer’s disease to improve cognition, memory, and behavior. In this way, it is intended to prevent or reverse dementia. Studies on these effects have been equivocal, indicating that more research into the therapeutic potential of donepezil is warranted.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.